World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
96
Citations
36347
World Ranking
9606
National Ranking
4949

Overview

Toby M. Maher is associated with the University of Southern California in the United States, focusing primarily on medical research within the field of pulmonary and respiratory medicine. Their scholarly contributions extensively address interstitial lung diseases and idiopathic pulmonary fibrosis.

Their recent publications include key works such as:

  • Global incidence and prevalence of idiopathic pulmonary fibrosis, 2021, Respiratory Research
  • Idiopathic pulmonary fibrosis: Disease mechanisms and drug development, 2020, Pharmacology & Therapeutics

Their research areas cover broad topics including systemic sclerosis and related diseases, pulmonary hypertension treatments, sarcoidosis and beryllium toxicity research, medical imaging and pathology studies, inhalation and respiratory drug delivery, and occupational and environmental lung diseases.

Toby M. Maher has collaborated frequently with other researchers in the field. Notable coauthors include Philip L. Molyneaux, Gísli Jenkins, Michael Kreuter, Marlies Wijsenbeek, and Vincent Cottin.

Their work has been published in a variety of scientific venues, with a high number of contributions in the following journals:

  • American Journal of Respiratory and Critical Care Medicine
  • Pneumologie
  • bioRxiv (Cold Spring Harbor Laboratory)
  • ERJ Open Research
  • European Respiratory Journal

Within the field of study, Maher's expertise lies mainly in Medicine, with a significant portion of research focusing on pulmonary and respiratory medicine, pathology and forensic medicine, physiology, epidemiology, and cardiology and cardiovascular medicine.

Best Publications

  • Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

    Oliver Distler;Martina Gahlemann;Toby M Maher

  • Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

    Collard Hr;Ryerson Cj;Corte Tj;Jenkins G

  • Interstitial lung disease in systemic sclerosis: a simple staging system.

    Nicole S. L. Goh;Sujal R. Desai;Srihari Veeraraghavan;David M. Hansell

  • Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.

    Tasha E. Fingerlin;Elissa Murphy;Weiming Zhang;Anna L. Peljto

  • The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis

    Phillip L. Molyneaux;Michael J. Cox;Saffron A. G. Willis-Owen;Patrick Mallia

  • Pulmonary fibrosis secondary to COVID-19: a call to arms?

    Paolo Spagnolo;Elisabetta Balestro;Stefano Aliberti;Stefano Aliberti;Elisabetta Cocconcelli

  • Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.

    Toby M Maher;Toby M Maher;Tamera J Corte;Tamera J Corte;Aryeh Fischer;Aryeh Fischer;Michael Kreuter

  • Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

    Athol U. Wells;Kevin R. Flaherty;Kevin K. Brown;Yoshikazu Inoue

  • Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?

    T M Maher;A U Wells;G J Laurent

  • Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes.

    Taryn L. Reddy;Masaki Tominaga;David M. Hansell;Jan von der Thusen

  • Idiopathic pulmonary fibrosis: Disease mechanisms and drug development.

    Paolo Spagnolo;Jonathan A. Kropski;Mark G. Jones;Joyce S. Lee

  • PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production

    Lindsay J. Celada;Jonathan A. Kropski;Jose D. Herazo-Maya;Weifeng Luo

  • Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury

    Chris J. Scotton;Malvina A. Krupiczojc;Melanie Königshoff;Paul F. Mercer

  • Short term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis.

    Nicole S. Goh;Rachel K. Hoyles;Christopher P. Denton;David M. Hansell

  • Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study

    R Gisli Jenkins;Juliet K Simpson;Gauri Saini;Jane H Bentley

  • Global incidence and prevalence of idiopathic pulmonary fibrosis.

    Toby M. Maher;Toby M. Maher;Elisabeth Bendstrup;Louis Dron;Jonathan Langley

  • Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease?

    Adam J. Byrne;Toby M. Maher;Clare M. Lloyd

  • Rituximab in severe, treatment-refractory interstitial lung disease.

    Gregory J. Keir;Toby M. Maher;Damien Ming;Reza Abdullah

  • Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study

    Richard J Allen;Joanne Porte;Rebecca Braybrooke;Carlos Flores

  • Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis

    Angelo De Lauretis;Piersante Sestini;Panagiotis Pantelidis;Rachel Hoyles

Frequent Co-Authors

Athol U. Wells
Athol U. Wells Imperial College London
Vincent Cottin
Vincent Cottin Claude Bernard University Lyon 1
Andrew G. Nicholson
Andrew G. Nicholson Royal Brompton Hospital
Martin Kolb
Martin Kolb McMaster University
David M. Hansell
David M. Hansell National Institutes of Health
Oliver Distler
Oliver Distler University of Zurich
Ganesh Raghu
Ganesh Raghu University of Washington
Luca Richeldi
Luca Richeldi Catholic University of the Sacred Heart
Christopher P. Denton
Christopher P. Denton University College London
Louise V. Wain
Louise V. Wain University of Leicester

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare degrees online can open up rewarding career options beyond traditional medical school. Many students interested in healthcare seek flexible academic routes that align with their personal or professional commitments.

For example, aspiring doctors of nursing may consider finding the easiest dnp program reddit users recommend, which often highlights programs with manageable coursework and supportive faculty. Likewise, those eager to enter the workforce quickly may explore reputable lpn online programs, which provide foundational nursing skills in a short timeframe and frequently offer accelerated paths to licensure.

If you're drawn to mental health specialties, many opt for accelerated msn psychiatric np programs, which combine speed and flexibility for licensed nurses who wish to become advanced practice providers. Additionally, those seeking leadership roles within healthcare settings might pursue one of the best online mha programs to gain management and administrative expertise.

Each of these online pathways caters to different interests and timelines, providing diverse opportunities within the growing field of healthcare.

Best Scientists Citing Toby M. Maher

Trending Scientists

Recently Published Articles